U.S. Application No.: 09/463,474 Attorney Docket No.: 8484-077-999

## APPENDIX B Serial No.: 09/463,474 Claims As Pending After Entry Of The Instant Amendment

٠,

- 1. (Thrice Amended) A conjugate for distinguishing cancerous or inflamed tissue from healthy tissue comprising a fluorescent moiety and a carrier, wherein the fluorescent moiety and the carrier are joined to one another via an acidic ester, an acidic amide bond or a Schiff base, and wherein said carrier is a protein.
- 2. (Reiterated) The conjugate of claim 13, wherein the serum albumin comprises a human serum albumin.
- 4. (Twice amended) A conjugate for distinguishing cancerous or inflamed tissue from healthy tissue comprising a fluorescent moiety and a carrier, wherein the fluorescent moiety and the carrier are joined to one another via an acidic ester, an acidic amide bond or a Schiff base, wherein said carrier is a protein, and wherein the conjugate comprises a plurality of carriers.
- 5. (Twice Amended) The conjugate of claim 1, wherein the fluorescent moiety comprises an acid group, a hydroxyl group, an amino group or an aldehyde group.
- 6. (Reiterated) The conjugate of claim 15, wherein the excitation wavelength is 630 to 850 nm.
- 7. (Twice Amended) The conjugate of claim 18, wherein the excitation wavelength is 320 to 450 nm.
- 8. (Twice Amended) The conjugate of claim 1, wherein the fluorescent moiety comprises a porphyrin, a chlorin, a bacteriochlorin, a chlorophyll, a phthalocyanine, a carboxy cinnamic acid, a carboxy cinnamic acid, a carboxyfluorescein, an acridic acid, a coumaric acid, or an indocyanine green.

U.S. Application No.: 09/463,474 Attorney Docket No.: 8484-077-999

9. (Twice Amended) A conjugate for distinguishing cancerous or inflamed tissue from healthy tissue comprising a fluorescent moiety and a carrier, wherein the fluorescent moiety and the carrier are joined to one another via an acidic ester, an acidic amide bond or a Schiff base, and wherein said carrier is a protein, and wherein the conjugate comprises a plurality of fluorescent moieties.

- 10. (Twice Amended) A method of producing the conjugate of claim 1, wherein the fluorescent moiety is covalently bonded to the carrier thereby forming the connector.
  - 13. (Amended) The conjugate of claim 1, wherein the protein is a serum albumin.
- 15. (Amended) The conjugate of claim 1, wherein the fluorescent moiety has an excitation wavelength of 630 nm or greater.
- 16. (Amended) A composition comprising the conjugate of claim 1 and an acceptable carrier or excipient.
- 18. (New) The conjugate of claim 1, wherein the fluorescent moiety has an excitation wavelength of 450 nm or less.